Skip to content

Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis

Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis With the ISIT-TB Prototype in Adults Living in a High Burden Setting

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04995406
Acronym
ISIT-TB
Enrollment
722
Registered
2021-08-09
Start date
2022-01-03
Completion date
2023-12-31
Last updated
2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TUBERCULOSIS, PULMONARY

Keywords

Tuberculosis, Mycobacterium infections, Bacterial infections, Diagnosis

Brief summary

ISIT-TB Prototype is a diagnostic assay based on a transcriptional blood signature suggestive of the detection of Mycobacterium tuberculosis.

Detailed description

This device will be investigated for use as a screening tool to facilitate diagnosis of ATB in conjunction with risk assessment, clinical context and diagnostic information. Whole blood samples will be collected in Tempus™ Blood RNA Tubes and processed on an automatized platform. The detection of a combination of under or over-expressed selected genes, constituting a transcriptional signature, will allow the characterization of ATB.

Interventions

DIAGNOSTIC_TESTISIT-TB prototype

Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Sponsors

BioMérieux
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Symptoms suggestive of TB disease: cough for more than two weeks plus at least one of the following: fever, malaise, weight loss, night sweats, haemoptysis, chest pain or loss of appetite. * Willingness to give consent to take part in the study. * Aged \>18 years old. * Healthy control : no history of TB treatment, no respiratory symptoms, no evidence of active infectious disease, no history of close contacts of active pulmonary TB patients.

Exclusion criteria

* Pregnant woman * A person who has received treatment for active TB or LTBI in the past 24 months

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of performance of the diagnostic toolTime to bacteriological confirmation 60 daysDetermination of the specificity and sensitivity of the diagnostic assay ISIT-TB Prototype for TB in a population living in a high-burden country

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026